Timber Pharmaceuticals, Inc. (TMBR): Price and Financial Metrics
GET POWR RATINGS... FREE!
TMBR POWR Grades
- TMBR scores best on the Growth dimension, with a Growth rank ahead of 59.37% of US stocks.
- The strongest trend for TMBR is in Sentiment, which has been heading down over the past 31 weeks.
- TMBR's current lowest rank is in the Stability metric (where it is better than 2.87% of US stocks).
TMBR Stock Summary
- TMBR has a higher market value than merely 3.38% of US stocks; more precisely, its current market capitalization is $26,541,612.
- With a price/sales ratio of 30.99, Timber Pharmaceuticals Inc has a higher such ratio than 92.76% of stocks in our set.
- The volatility of Timber Pharmaceuticals Inc's share price is greater than that of 94.69% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Timber Pharmaceuticals Inc are NAVB, KMDA, SONM, UTSI, and AEIS.
- Visit TMBR's SEC page to see the company's official filings. To visit the company's web site, go to www.timberpharma.com.
TMBR Valuation Summary
- TMBR's price/earnings ratio is -25.2; this is 169.04% lower than that of the median Healthcare stock.
- TMBR's price/sales ratio has moved NA NA over the prior 76 months.
- Over the past 76 months, TMBR's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for TMBR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TMBR | 2021-08-31 | 39.5 | 12.1 | -25.2 | -24.3 |
| TMBR | 2021-08-30 | 39.4 | 12.0 | -25.2 | -24.2 |
| TMBR | 2021-08-27 | 40.3 | 12.3 | -25.8 | -24.9 |
| TMBR | 2021-08-26 | 40.1 | 12.2 | -25.6 | -24.7 |
| TMBR | 2021-08-25 | 39.1 | 12.0 | -25.0 | -24.0 |
| TMBR | 2021-08-24 | 39.5 | 12.1 | -25.2 | -24.3 |
TMBR Stock Price Chart Interactive Chart >
TMBR Price/Volume Stats
| Current price | $0.71 | 52-week high | $3.65 |
| Prev. close | $0.72 | 52-week low | $0.67 |
| Day low | $0.70 | Volume | 532,800 |
| Day high | $0.75 | Avg. volume | 4,226,795 |
| 50-day MA | $0.91 | Dividend yield | N/A |
| 200-day MA | $1.33 | Market Cap | 26.21M |
Timber Pharmaceuticals, Inc. (TMBR) Company Bio
Timber Pharmaceuticals, Inc. operates as a biotech company. The Company develops treatments for rare skin diseases. Timber Pharmaceuticals serves customers in the State of New Jersey.
Latest TMBR News From Around the Web
Below are the latest news stories about Timber Pharmaceuticals Inc that investors may wish to consider to help them evaluate TMBR as an investment opportunity.
Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital IchthyosisData demonstrate reduction in targeted and overall severity of CI in patients treated with topical IPEG™ TMB-001 (topical isotretinoin) Company planning for end-of-Phase 2 meeting with FDA in the beginning of 2022 Phase 3 study is expected to begin in Q2 2022 Basking Ridge, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatme |
Timber Pharmaceuticals Presents at EADV’s 30th Anniversary CongressBasking Ridge, N.J., Oct. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it is presenting at the European Academy of Dermatology and Venereology’s (EADV) 30th anniversary congress being held virtually from September 29-October 2, 2021. The topic of the Company’s |
Timber Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceBASKING RIDGE, NJ, Sept. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The Conference will be held virtually with all participants joining remotely from September 13th - 15th, 2021. |
Timber Pharmaceuticals Announces Last Patient Last Visit in Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis- Topline results expected to be announced in the fourth quarter of 2021 - - Company preparing for an End-of-Phase 2 meeting with the FDA - Basking Ridge, N.J., Aug. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the last patient completed their last visit in the |
7 Hottest Penny Stocks to Pick Up NowPenny stocks from companies that have reasonable business fundamentals. |
TMBR Price Returns
| 1-mo | -25.26% |
| 3-mo | -26.04% |
| 6-mo | -42.74% |
| 1-year | -31.73% |
| 3-year | -98.75% |
| 5-year | -99.28% |
| YTD | -4.44% |
| 2020 | -85.40% |
| 2019 | -84.58% |
| 2018 | 0.00% |
| 2017 | -70.27% |
| 2016 | -75.66% |
Loading social stream, please wait...